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COMBINATION ANTI-LEUKEMIC THERAPY 
BY UTILIZING SURAMIN AND BIOLOGIC 
RESPONSE MODIFIERS 
RELATED APPLICATIONS 
This application claims priority from provisional patent 
application Ser. No. 60/039,260, ?led Feb. 26, 1997 entitled 
“COMBINATIONANTI-LEUKEMIC THERAPY BY UTI 
LIZING SURAMIN AND BIOLOGIC RESPONSE 
MODIFIERS”, Which is incorporated herein by reference. 
TECHNICAL FIELD 
The present invention relates to a combination of anti 
leukemic therapy utilizing suramin and biological response 
modi?ers. The anti-groWth factor suramin is used in com 
bination With several different biologic response modifying 
agents such as all-trans retinoic acid (ATRA) and interferon 
ot. Synergistic activity betWeen the compositions Was shoWn 
With these therapies. 
BACKGROUND ART 
US. Pat. No. 5,158,940 to LaRocca et al., issued Oct. 27, 
1992. This patent discloses in col. 1 and col. 2 that suramin, 
a polysulfonated napthtylurea has a demonstrated ability to 
inhibit the activity of various groWth factors in vivo. 
Suramin is knoWn to treat rheumatoid arthritis and related 
diseases. The ’940 patent discloses the usefulness of suramin 
against autoimmune and allergenic diseases such as Crohn’s 
disease, ulcerative colitis, sarcoidosis, rheumatoid arthritis, 
scleroderma, polyarteritis, psoriasis, interstitial and glom 
erular nephrites, systemic lupus erythematosus, 
polymyositis, Sjogren’s syndrome, asthma and other in?am 
matory alveolar disorders. 
US. Pat. No. 4,591,604 discloses a method of inhibiting 
the complement system by administering multisulfonated 
naphthalene ureas (see col. 6, line 7). 
US. Pat. No. 4,459,293 discloses a method of modulating 
the complement system by administering arylene sulfate 
derivatives and their cation salts. 
US. Pat. No. 4,414,207 discloses sulfate and salts thereof 
and their use as inhibitors of the complement system. The 
complement system is stated in col. 1, lines 39 to 46 to play 
an important role as a mediator of immune, allergic, immu 
nochemical and/or immunochemical and/or immunopatho 
logical reactions. Col. 3, line 45 indicates that suramin 
compounds are knoWn for inhibiting the complement sys 
tem. 
US. Pat. No. 4,407,796 discloses modulators of the 
complement system and describes in col. 6, line 10 that 
suramin sodium is knoWn for the treatment of hereditary and 
angioneurotic edema. 
US. Pat. No. 4,393,055 discloses in sulfate derivatives 
and their use as complement inhibitors. Col. 4, line 64 
describes that suramin sodium is useful in the treatment of 
hereditary angioneurotic edema. 
US. Pat. No. 4,387,059 discloses 6-naphthalenetri 
sulfonic acid salts. Col. 4, line 57 describes that suramin 
sodium is knoWn for the treatment of hereditary angion 
eurotic edema. 
US. Pat. No. 4,371,524, discloses anti-complementary 
agents comprising soyasapogenol B compounds. Col. 4, line 
17 discloses that suramin sodium is knoWn as a complement 
inhibitor. 
US. Pat. No. 4,304,903, discloses at col. 3, line 37 that 
suramin is knoWn as a complement inhibitor. 
US. Pat. No. 4,266,077, discloses at col. 3, line 23 that 
suramin is knoWn as a complement inhibitor. 
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US. Pat. No. 4,232,150, discloses at col. 5, line 16 that 
suramin sodium is knoWn for the treatment of hereditary 
angioneurotic edema. 
US. Pat. No. 5,585,243, discloses at col. 10, line 34 that 
suramin sodium causes antibody dependent drug-induced 
thrombocytopenia. 
Chemical Abstracts Vol. 124, No. 3, Abstract No. 21284q, 
published in 1996 discloses the inhibition of granulocyte 
macrophage colony-stimulating factor activity by suramin 
and suramin analogs. This action is correlated to interaction 
With the GM-CSF nucleotide-binding site. This publication 
has a publication date of 1995. 
Chemical Abstracts Vol. 118, No. 21, Abstract No. 
204843s, published in 1996 describes the suppression of 
polymorphonuclear leukocyte bactericidal activity by 
suramin. 
Chemical Abstracts Vol. 92, No. 11, Abstract No. 88004n, 
published in 1980 describes blockage of the macrophage 
system and blood lipids With suramin. 
Chemical Abstracts Vol. 97, No. 7, Abstract No. 54457b 
With a publication date of 1979. This publication describes 
the effect of suramin on phago-lysosome formation by 
poly-glutamic in mycobacterium infection. 
Chemical Abstracts Vol. 89, No. 11, Abstract No. 84580n, 
published in 1978. This publication describes suramin 
effects on macrophage phagolysosome formation and anti 
microbial activity. 
Chemical Abstracts Vol. 101, No. 7, Abstract No. 48367f, 
published in 1984 describes phagocytic and candidacidal 
activity on alveolar macrophages from suramin-treated 
mice. Chemical Abstracts Vol. 100, No. 23, Abstract No. 
185492m, 1984, describes the in?uence of suramin and 
cyclophosphamide administered in combination on alveolar 
macrophages. 
Chemical Abstracts Vol. 100, No. 15, Abstract No. 
114605q, 1984, describes the effect of suramin on pinocy 
tosis by rat peritoneal macrophages. 
Chemical Abstracts Vol. 99, No. 1, Abstract No. 215t, 
1993 describes the lung macrophage defense responses 
during suramin-induced lysomal dysfunction. 
Chemical Abstracts Vol. 109, No. 25, Abstract No. 
221980r, 1988, describes the modulation by suramin of NK 
and monocytic cell-mediated cytotoXicity in human and 
murine cells. 
Chemical Abstracts Vol. 108, No. 23, Abstract No. 
198002s, 1988, describes the activation of chicken perito 
neal macrophages by suramin. 
Chemical Abstracts Vol. 123, No. 19, Abstract No. 
246203s, 1995, describes the immunoprotective and immu 
nological activities of suramin in hamsters With myeloid 
tumor. 
Chemical Abstracts Vol. 121, No. 9, Abstract No. 99107s, 
1994, describes the in?uence of suramin on the expression 
of Fc receptors and other markers of human monocytes and 
U937 cells. 
Chemical Abstracts Vol. 115, No. 7, Abstract No. 64775g, 
describes the use of suramin to treat rheumotologic diseases. 
Chemical Abstracts Vol. 125, No. 13, Abstract No. 
158032W, describes the immunopharmalogical effect of 
suramin on modifying TH subset cytokine levels in spleen 
cites and T-cell clones. Also describes as a therapeutic 
application for autoimmune disease. 
Abstract published Mar. 1, 1996 by Doukas et al. dis 
closes that all-trans retinoic acid (ATRA) and suramin had 
synergistic activity in interrupting autocrine driven leukemic 
cell groWth. 
LopeZ et al., European Journal of Cancer Research, The 
Synergistic and Antagonistic Effects of Cytotoxic and Bio 
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logical agents on the In Vitro Antitumor Effects of Suramin, 
Vol. 30A, No. 10, pp. 1545—1549, (1994) discloses that 
suramin and ot-interferon and y-interferon did not have 
synergistic activity against PL-3 tumor cell line. 
There is a need in the art for neW leukemia treatments. 
The present invention overcomes de?ciencies of prior art 
leukemia treatments. 
DISCLOSURE OF THE INVENTION 
The present invention relates to a method of treating 
leukemia comprising administering an effective amount of 
composition comprising suramin and a biological response 
modi?er. In a preferred embodiment, said suramin and said 
biological response modi?er shoW synergistic anti-leukemic 
activity. 
In a preferred embodiment the biologic response modi?er 
is selected from the group consisting of all-trans retinoic 
acid (AT RA), ot-interferon y-interferon, vitamin D, 9-cis 
retinoic acid, cytosine arabinoside, adriamycin, 
mitoXantrone, VP-16, idarubicin and tumor necrosis factor. 
The invention also relates to a pharmaceutical composi 
tion comprising suramin and a biological response modi?er. 
In the composition the suramin and the biological response 
modi?er shoW synergistic anti-leukemic activity. 
In a preferred embodiment the biologic response modi?er 
is selected from the group consisting of all-trans retinoic 
acid (ATRA), interferon-0t, y-interferon, vitamin D, 9-cis 
retinoic acid, cytosine arabinoside, adriamycin, 
mitoXantrone, VP-16, idarubicin and tumor necrosis factor. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. 1A and 1B shoW HL60 leukemia cell proliferation 
after administration With suramin and ot-interferon. 
FIG. 2 shoWs suramin plus ATRA strongly inhibited 
HL-60 and HL-60R groWth. Analysis utiliZing a softWare 
program reveals that this activity is a truly synergistic one. 
FIG. 3 shoWs ATRA plus suramin also inhibited HL-60R. 
FIG. 4 shoWs alpha interferon given in combination With 
suramin inhibits the proliferation of HL-60 cells in a syn 
ergistic fashion. 
FIG. 5 shoWs interferon Was given for the initial 48 hours 
of incubation folloWed by an additional 72 hours during 
Which both interferon and suramin Were present, the results 
Were not only synergistic, but shoWed greater activity than 
the simple combination together. 
FIG. 6 shoWs synergism With the combination of 
ot-interferon and suramin Were also noted against the 
HL-60R cell line at doses greater than 25 mM suramin and 
5,000 units/ml ot-interferon. 
FIG. 7 shoWs the addition of suramin and interferon 
together for a 5-day incubation shoWed additive activity 
against HL-60. 
FIG. 8 shoWs additive activity against HL-60 for suramin 
and ARA-C. 
DESCRIPTION OF THE INVENTION 
Retinoid compounds (vitamin A derivatives) When used in 
conjunction With pharmacologic antigroWth factor agents 
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(suramin and analogs) can result in synergistic activities 
against myeloid leukemias. Objectives of the invention 
include in vitro testing using human leukemic cell lines 
derived from patients With acute promyelocytic leukemia 
(NB4) and acute myeloid leukemia (HL-60) to ?rst ascertain 
the most advantageous combinations to inhibit these leuke 
mia cell lines. Compounds tested include all-trans retinoic 
acid (ATRA), in combination With suramin or its most potent 
analog, NF110. Other analogues include NF032, NF201, 
NF023, NF103 and the class of compounds knoWn as azo 
dyes. 
The invention alloWs for a treatment of leukemia and 
eXpands the use of retinoids into other forms of leukemia 
other than acute promyelocytic leukemia, Which is the form 
of leukemia Which has seen the greatest usefulness of 
retinoids. This is directly relevant to the role of vitamin 
nutrients in the treatment of certain malignancies, in this 
case leukemias, and alloWs for treatment of malignancy by 
drugs With better activity and Which do not have the side 
effects of standard chemotherapy. 
The retinoids are vitamin Aanalogs that play a critical role 
in normal differentiation and groWth The oXidiZed form 
of vitamin A is important in maintaining epithelial cellular 
integrity Retinoid therapy of some hematopoietic and 
non-hematopoietic models inhibits carcinogenesis The 
greatest therapeutic triumph of retinoid analogs rests With 
the use of all-trans retinoic acid (ATRA) in acute promy 
elocytic leukemia (APL) This compound stimulates the 
clonal groWth of normal hematopoietic progenitors yet 
inhibits the groWth of HL-60 and NB4 cells (acute myeloid 
and acute promyelocytic leukemia cell lines, respectively) 
(5). Its usage as a single agent results in complete remission 
rates in APL of 70% or better (4,6). The remarkable activity 
of ATRA in this particular leukemia is knoWn to correspond 
to the speci?c chromosomal translocation t (15,17) Which 
results in the fusion product, PML/RARa (promyelocytic 
leukemia/retinoic acid receptor-a). The PML/RARa chi 
meric protein appears to function as a “dominant-negative” 
retinoid receptor, thus blocking the normal maturation of 
promyelocytes The precise function of PML/RARa is 
being intensively studied, and it appears that, ATRA clini 
cally restores the capacity of APL cells to terminally differ 
entiate With resultant apoptosis and hence disappearance of 
leukemic blasts. 
This maturation process of APL cells is associated With 
the “ATRA syndrome” in a subset of patients (5—20%) 
reported. This is characteriZed by fever, respiratory distress 
and chest X-ray abnormalities, and Weight gain Several 
important caveats of ATRA responses in APL are critical in 
the long-term prognosis. First, ATRA remissions are brief 
(8). This is an interesting phenomenon and may relate to 
altered pharmacokinetics With prolonged therapy (9) or to 
the development of intrinsic cellular resistance (10). A 
proportion of patients (60%) may enjoy long term remis 
sions When ATRA treatment is folloWed by chemotherapy 
(6). HoWever, 30—40% of patients are either resistant to 
ATRA at diagnosis or relapse, and are thus unlikely of being 
cured by conventional therapy. Other clinical oncology trials 
of retinoids include their use (13-cis retinoic acid or ATRA) 
in the myelodysplastic syndrome With miXed results (11,12), 
in chronic myelogenous leukemia (vitamin A) With a sig 
ni?cant improvement in overall survival When used in 
conjunction With chemotherapy (6), and pilot trials (13-cis 
retinoic acid) in cervical cancer used in conjunction With 
interferon-0t (13,14). The combination trials are accompa 
nied by some in vitro laboratory data Which indicate that 
retinoids may have ef?cacy if used in combination With 
appropriately chosen agents that render not additive, but 
rather synergistic activity (15). 
One such combination approach involving retinoids, 
Which doWn-regulate certain cytokine receptors on tumor 
6,121,320 
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cells, coupled With antigroWth factor agents Which block 
cytokine-receptor interaction and hence both Work to inter 
rupt malignant cell autocrine growth factor loops (16). Such 
autocrine mechanisms exist in leukemias (and certain solid 
tumors) and Would be a novel approach to improving cure 
rates in APL therapy and reduce the incidence of the 
development of resistance Which has been correlated With 
neW leukemia cell cytokine production (17). Appropriate 
combination therapies may also be useful in expanding 
retinoid efficacy in other leukemias in Which autocrine 
groWth mechanisms have been proposed. 
Granulocyte/macrophage-colony stimulating factor (GM 
CSF) is a cytokine Which has a broad range of proliferative, 
differentiating, and activating effects upon in?ammatory 
cells and their precursors (18,19). Recent Work in our 
laboratories has resulted in the description of previously 
unknoWn nucleotide binding interactions With several 
cytokines, speci?cally interleukin (IL)-2 (20), interleukin-1 
(21), acidic FGF (22), and GM-CSF (23). The nucleotide 
binding site for GM-CSF appears by virtue of saturation and 
competitive binding studies to have speci?city for adenosine 
nucleotide probes. Our Work has revealed that the anti 
groWth factor agent suramin strongly interacts With this 
binding site (24) and our data support our hypothesis that 
this interaction may be central to its inhibitory activity on 
cellular proliferation. 
Suramin’s history dates to the early German organic 
chemical industry (25) and the discovery that it Was an 
active antitrypanosomal agent (26). Hawking noted that the 
drug could bind to and inhibit many enZymes Without an 
apparent underlying unifying theme (27). Interest sharpened 
With the discovery of inhibition of reverse transcriptase and 
several groWth factors, the latter leading to clinical trials in 
prostate cancer (28). GroWth factors (cytokines) have been 
shoWn to act as autocrine stimulators of a variety of normal 
hematopoietic cell types and acute leukemias (2931). Sub 
sequent research proceeded on the hope that certain malig 
nant tumors Would be more sensitive than normal tissues 
(28). 
An important, perhaps central, feature of suramin is its 
capacity to interfere With cytokine-receptor binding. In the 
class of hematopoietic cytokines, IL-2 and IL-6, share this 
effect (32,33). The precise mechanism is controversial With 
con?icting reports of altered cytokine quaternary structure 
With changes of deoligomeriZation (TNF-a) on the one hand 
(34), and aggregation (FGF and PDGF) on the other (35). 
Other activities upon a Wide variety of cellular enZymes 
have been described (36—40) and, paradoxically in relation 
to its anti-groWth factor action, an increase in protein 
tyrosine phosphorylation has been reported (41). It should 
be noted hoWever that all of these studies involved cell 
culture and not isolated enZyme systems; the mechanism and 
pathWays by Which suramin affected each of these enZymes 
is unclear. In sum, the antigroWth factor activity via 
cytokine-receptor blockade, Which agrees With our data on 
GM-CSF, appears to be a constant theme across multiple 
cytokines. 
In spite of the demonstrated autocrine groWth promoting 
role of cytokines such as GM-CSF and IL-1 in leukemia (31, 
42—45), little Work has been published With suramin’s use 
for hematopoietic malignancies. In one study, ?ve of nine 
evaluable follicular lymphoma patients achieved a partial 
remission of their disease With suramin (46). HoWever, With 
the exception of four patients With agnogenic myeloid 
metaplasia (a chronic myeloproliferative disorder) (47), 
MEDLINE search revealed no suramin trials in myeloid 
leukemia. Suramin does strongly suppress in vitro the pro 
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liferation of the HL-60 acute leukemic cell line (48) and the 
Work of Orchard (49) agrees With our ?nding of suramin 
inhibition of GM-CSF dependent cell groWth (24). 
Autocrine groWth factor loops involving cytokines have 
been implicated as important in the groWth of certain tumors 
and leukemias. The Work of the inventors has shoWn that 
suramin is a potent agent against leukemic cells in vivo and 
has been expanded to include several suramin analogs. Due 
to the toxicities of suramin, the effectiveness of suramin 
used in combination With biologic agents speci?cally, all 
trans-retinoic acid (ATRA) has been studied. The goal Was 
to ascertain if such combinations are merely additive or are 
synergistic. 
All trans-retinoic acid has been found to be an effective 
agent for induction of remission When used as a single agent 
in acute promyelocytic leukemia and other retinoids are 
under study both as maintenance agents in acute leukemia 
and in other solid tumors. The possibility that such combi 
nations are synergistic assists in dosing patients With 
suramin at levels Which are less toxic and yet result in 
greater activity. 
Cell lines Which have been selected for ATRA resistance 
are utiliZed to examine if synergism remains or is abrogated 
With these retinoid resistant cell lines. Cell lines chosen for 
this study include the ATRA sensitive human acute leukemia 
HL-60 and ATRA sensitive APL line, NB4, both of Which 
have been extensively studied. An ATRA resistant sub clone, 
HL-60R Was obtained from Dr. Steve Collins. While origi 
nally described as an acute promyelocytic cell line, more 
recent Work categoriZes this line as an acute myelogenous 
leukemia. Therefore, a second ATRA resistant line 
(NB4.306) Which is derived from the NB4 cell line from a 
patient With acute promyelocytic leukemia Was obtained. 
The NB4tNB4.306 lines contain the t(lS,17) typical of APL. 
The sensitivity of these cell lines to ATRA and suramin (or 
NF110) as single agents is assessed. ATRA dose response 
curves (10-5—10-9M) are generated as are suramin/analogue 
dose response curves (10-4—10-8M). These data for each 
individual cell line alloW description of describe IC50 
concentrations for the individual agents, and in the case of 
suramin analogues, permit comparison of ef?cacy. 
Assays of proliferation consist of cell proliferation (3H 
thymidine) assay as previously described or the MTT assay 
after 3—5 days of exposure to the agents. Cell proliferation 
is assayed using a modi?cation of the original MTT calo 
rimetric assay described by Mosmann (53). To better delin 
eate the issues of proliferation (and inhibition thereof) 
versus differentiation, Which is induced by certain of the 
agents being proposed for testing, an alternative method 
Would utiliZe simple cell counting (Courter, Inc.) of aliquots 
at 3 and 5 days of continuous exposure With concomitant 
analysis of induced differentiation by cell morphology 
(NBT-positive) conducted. The percentage of differentiated 
cells in liquid culture determined by the NET reduction test 
(as described, (54) alloWs for an estimate of the total number 
of cells Which are still blast cells and therefore considered 
capable of continued leukemogenic groWth. The most prom 
ising combinations are used to examine de novo acute 
myeloid leukemia patient samples in like fashion. 
A SCID mouse host system is utiliZed and the most 
promising agent combinations are examined to determine 
the response of human leukemic cell lines in these host 
animals. Finally, the potential mechanisms of the ATRA/ 
suramin synergistic activity as it relates to cytokine receptor 
density on treated human leukemia cell lines is examined. 
Mechanisms of action and clinically relevant studies With 
retinoids in combination With antigroWth factor agents to 
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improve the therapeutic index or expand the use of retinoids 
into other myeloid leukemias other than acute promyelocytic 
leukemia. 
The Work has direct relevance to the role of vitamin 
nutrients in the treatment of selected malignancies, in this 
case myeloid leukemias, and broadens the applications of 
retinoids by proving the theoretical unexpected advantage of 
combination usage With antigroWth factor agents. 
The antigroWth factor activity of suramin Was tested alone 
and in combination With all-trans retinoic acid (ATRA) 
against the human leukemic line HL-60 or its ATRA resis 
tant subclone, HL-60R, to assess if an agent With the ability 
to interrupt putative autocrine driven leukemic cell groWth 
could reestablish sensitivity to ATRA. Using the MTT 
cytotoxicity assay, comparison of ED50 values of suramin 
alone revealed HL-60 cells to be more resistant than HL60R 
(38.7 vs. 1 3.4,uM). Synergy or antagonism betWeen com 
binations Was then assessed using a combination-index 
CI-isobolo gram method. Combinations of suramin (3.5—56 
pM) and ATRA (0.001—0.16 pM) at a ratio of 350:1 shoWed 
synergy With a mean CI value of 0.72+0.06 SD (0.61—0.79) 
With the HL-60 cell line. HoWever With HL-60 R cells, these 
combinations Were antagonistic With CI values of 1.40+0.21 
(1.13—1.63) despite greater sensitivity to suramin alone. 
Combination studies With suramin and cytosine arabinoside 
Were not synergistic With HL-60 cells, but did shoW additive 
activity. While suramin addition Was not useful in restoring 
ATRA sensitivity, the combination Was synergistic With 
ATRA sensitive HL-60 leukemic cells. In this human leu 
kemia model, suramin in combination With the differentiat 
ing agent ATRA offers a novel treatment approach. 
Methods 
Cell lines chosen for this study include the ATRA sensi 
tive human acute leukemia HL-60 and the ATRA resistant 
subclone, HL-60R. While originally described as an acute 
promyelocytic cell line, more recent Work categoriZes this 
line as an acute myelogenous leukemia. The sensitivity of 
these cell lines to AT RA and suramin alone as single agents 
has been assessed. These data permit the description of the 
IC50 concentrations for the individual agents. The assays of 
proliferation consist of cell proliferation after 3—5 days of 
exposure to the agents. Cell proliferation is assayed using a 
modi?cation of the original MTT calorimetric assay 
described by Mossman, et al. In similar fashion, a dose 
response curve to cytosine arabinoside has been generated. 
Using the IC50 values for each agent alone alloWs selection 
of reasonable drug combinations. The data softWare 
program, “Dose effect analysis With microcomputers” 
(BioSoft, Inc.) developed by Dr. Chou, et al. is utiliZed. This 
computer analysis program alloWs the assessment of drug 
combinations for synergistic, additive, or antagonistic inter 
actions. 
Compounds related to vitamin AWhen used together With 
drugs that inhibit groWth factor related tumor cell groWth 
result in greatly increased activity against certain forms of 
leukemia. The compounds Which are related to vitamin A are 
knoWn as retinoids and the drug Which inhibits groWth factor 
related tumor cell groWth is knoWn as suramin. The inven 
tors observe the groWth of human leukemia cell lines in 
laboratory culture Which Were originally obtained from 
patients With diseases knoWn as acute promyelocytic leuke 
mia and acute myeloid leukemia to ?rst discover the most 
useful combinations of retinoids plus suramin to inhibit the 
leukemia cell lines. Each of several retinoid compounds are 
tested in combination With suramin or a very potent analog, 
NF110. Leukemia cell lines Which are resistant to retinoids 
are tested to see if they remain sensitive to the combination 
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or are resistant also to the combination of retinoids With 
suramin. The most promising combinations are tested 
against fresh acute leukemia patient samples. All of the 
testing Which has been done in laboratory culture are exam 
ined in an animal model system of human leukemia cell 
groWth. Finally, possible mechanisms of Why retinoids plus 
suramin have such greatly increased activities is studied. 
The invention combines certain vitamin analogs 
(retinoids), When used in conjunction With anti-groWth fac 
tor agents (suramin and analogs), and can result in syner 
gistic activities against certain myeloid leukemias. 
To de?ne these activities, the rationale for such 
synergism, and preclinical models to examine the potential 
for anti-leukemic treatment include; 
1. UtiliZing in vitro human leukemia models, de?ne the 
capacity for synergism betWeen retinoids and suramin/ 
analogs and the most advantageous doses and sequenc 
ing. 
a.) UtiliZing retinoic acid sensitive human leukemic cell 
lines (NB4) derived from an acute promyelocytic leu 
kemia (APL) patient, examine the activity of all-trans 
retinoic acid (ATRA), 9-cis retinoic acid, and 13-cis 
retinoic acid in combination With suramin or its most 
potent analog (see section H), NF110. 
b) UtiliZing a retinoic acid sensitive human myeloid 
leukemic cell line (HL60) derived from an acute 
myeloid leukemia (AML) patient, examine in like 
fashion the retinoids (as above) In combination With 
suramin/NF110. 
c) Examine in the above models if sequential therapy 
(retinoids folloWed by the addition of suramin, or the 
converse) is superior to simple combination therapy. 
d) UtiliZing cell lines selected for retinoid resistance 
(NB4.306, HL-60R) examine if synergism With com 
bination therapy is retained or abrogated. 
e) Take the most promising combination as de?ned above, 
and examine the in vitro activity against de novo acute 
myeloid leukemia patient samples. 
2. UtiliZing the SCID mouse host system, take the most 
promising agent combinations and examine the 
response of human leukemia cell lines in the SCID 
mouse hosts. 
3. Investigate potential mechanisms of the AT RA/suramin 
synergistic activity as they relate to cytokine receptor 
availability on treated human leukemia cell lines. 
Previous publications disclose a novel nucleotide binding 
site on murine and human granulocyte/macrophage-colony 
stimulating factor (GM-CSF) Which is critical to the biologic 
activity of this cytokine. The inventors have subsequently 
shoWn that a pharmacologic antigroWth factor agent, 
suramin, interacts With the GM-CSF binding site and inhib 
its GM-CSF dependent cell groWth. 
Acute myeloid leukemic (AML) cells produce cytokines, 
possess their receptors, and in 70% of patients With AML 
have evidence of in vitro autonomous groWth related to 
autocrine groWth factor loops, particularly With GM-CSF 
(31) and IL-1 (42—45). The effect of suramin on HL-60 
human leukemic cells Was examined and inhibition resulted 
as has been previously noted (48). A graphical correlation 
Was then generated Which shoWs a very agreeable correla 
tion as regards rank ordering of inhibition of both nucleotide 
binding and leukemia proliferation (Table 1). NF110 has 
been discovered to have a greatly enhanced activity (5—10 
fold) against HL-60 and the HL-60R (trans retinoic acid 
resistant) cell line (FIG. 1). 
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TABLE 1 
Inhibitory Potency of Suramin and Suramin Analogs: 
Competition curves for nucleotide, photoprobe 
incorporation into rhGM-CSF gave half-maximal 
inhibitions of photoprobe incorporation as compared to 
control. Similarly, cell proliferating of GM-CSF 
dependent (Mo7E) and autonomously proliferation (GM-CSF 
independent) human leukemia cells (HL-60) gave half 
maximal inhibition of growth. Results are expressed as 
micromolar concentrations. 
Half-maximal 
Half-maximal inhibition 
Half-maximal inhibition of of HL-60 
inhibition of Mo/7E growth growth (GM 
nucleotide (GM-CSF CSF 
Compound binding dependent) independent) 
NF110 1.5 52 6 
suramin 2.5 68 38 
NF302 2.0 76 80 
NF201 2.3 76 155 
NF023 5.0 102 175 
NF103 16.0 141 not reached 
Suramin plus ATRA strongly inhibited HL-60 and 
HL-60R growth. The data software program, “Dose Effect 
Analysis with Microcomputers” (Biosoft, Inc.) (50—52) has 
analyzed a number of experiments utilizing combinations of 
ATRA and suramin. The analysis utilizing the software 
program now reveals that this activity is a truly synergistic 
one (FIG. 2). 
Table 2 displays the fractional inhibition by each agent 
singly and in combination against HL-60. Single drug dose 
effect relationship parameters (Dm, m, and r) were calcu 
lated for suramin (D1) and ATRA (D2). 
TABLE 2 
Example of experimental design and dose-effect 
relationship of suramin and all-trans retionoic acid 
(ATRA) and their combination on the growth of HL60 
cells after 5 days exposure: 
The parameters m, Dm, and r are the slope, antilog 
of x-intercept, and the linear correlation coef?cient 
of the median-effect plot, which signi?es the shape of 
the dose-effect curve, the potency (ICSU), and 
conformity of the data to the mass-action law, respectively. 
Dm and m values are used for calculating the CI values. 
CI < 1, CI = 1, and CI > 1 indicate synergism, 
additivity, and antagonism, respectively. As based on the 
classic isobologram equations, CI can be calculated by the 
equation CI = [<D>./<DX>.1+ [wk/(13.92], Where 
Dx = Dm[fa/1 — fa)]1, and where fa = fractional inhibition. 
HL 60 Cells 
Suramin ATRA Fractional 
(,uM) Inhibition m Dm r CI 
3.5 .020 
7.0 .047 
14.0 .093 
28.0 .419 
56.0 .678 1.725 38.6658 .98606 
.001 561 
.01 .777 
.02 .790 
.04 .823 
.08 .826 
.16 .835 .2729 .00022 .95094 
D1 + D2 
(350:1) 
3.5 .01 .764 .69631 
7.0 .02 .806 .6175 
14.0 .04 .831 .75907 
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TABLE 2-continued 
Example of experimental design and dose-effect 
relationship of suramin and all-trans retionoic acid 
(ATRA) and their combination on the growth of HL60 
cells after 5 days exposure: 
The parameters m, Dm, and r are the slope, antilog 
of x-intercept, and the linear correlation coe?icient 
of the median-effect plot, which signi?es the shape of 
the dose-effect curve, the potency (ICSU), and 
conformity of the data to the mass-action law, respectively. 
Dm and m values are used for calculating the CI values. 
CI < 1, CI = 1, and CI > 1 indicate synergism, 
additivity, and antagonism, respectively. As based on the 
classic isobologram equations, CI can be calculated by the 
equation CI = [<D>./<DX>.1+ [wk/(13.92], Where 
Dx = Dm[fa/1 — fa)]1, and where fa = fractional inhibition. 
HL 60 Cells 
Suramin ATRA Fractional 
(,uM) Inhibition m Dm r CI 
28.0 .08 .867 .72063 
56.0 .16 .897 .3505 .12781 .996 .78735 
From studies of single drug, the dose ranges were selected 
to cover the concentrations above and below the IC-50 
values of each agent. This led to the generation of the 
combination indices (CI) based on the classic isobologram 
equation. Results showed de?nite synergism (CI values less 
than 1) with the HL-60 cell line and this combination (Table 
2, FIG. 2). ATRA plus suramin also inhibited HL-60R (FIG. 
3), synergism was encountered only at the higher doses per 
the computer analysis. 
In similar fashion, (X-IHICI‘fCI‘COIl given in combination 
with suramin inhibits the proligeration of HL-60 cellls in a 
synergistic fashion (FIG. 4). In a related experiment, when 
interferon was given for the initial 48 hours of incubation 
followed by an additional 72 hours during which both 
interferon and suramin were present, the results were not 
only synergistic, but showed greater activity than the sim 
eple combination together (FIG. 5). Synergism with the 
combination of (X-IHIGI‘fGI‘OIl and suramin were also noted 
against the HL-60R cell line at doses greater than 25 mM 
suramin and 5,000 units/ml (X-IHIGI‘fGI‘OIl (FIG. 6). Finally, 
the addition of suramin and interferon together for a 5-day 
incubation showed additive activity against HL-60 (FIG. 7), 
and for suramin and ARA-C (FIG. 8). 
The capacity to perform the detailed dose-effect combi 
nation drug analyses which support our hypothesis regarding 
potential synergism of the suramin class agents with retinoid 
compounds. 
Differentiation agents, speci?cally ATRA, are used in the 
treatment of acute promyelocytic leukemia (APL) and other 
retinoids are in clinical trials with other acute myeloid 
leukemias (7,8). The ef?cacy of ATRA to induce terminal 
differentiation (thus depleting the leukemic blast population) 
is proven; however, recrudescence of leukemia after a short 
period of complete remission is common and new autocrine 
growth factor loops have been proposed as one mechanism 
of resistance Suramin has anti-growth factor activity 
against HL-60, a human acute leukemia cell line sensitive to 
ATRA (48). The possibility that agents with anti-growth 
factor activity can provide additive or synergistic effects 
upon ATRA sensitive and AT RA resistant leukemia cell lines 
was explored. The mainstay of therapy for acute leukemia 
remains chemotherapy. However, for adults, a 60—70% 
initial complete remission rate results in only 20—25% 
long-term survivorship (excepting APL with 60% long-term 
survivorship with AT RA plus chemotherapy). Alternatively, 
direct assessment of cells capable of forming colonies, 
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colony forming unit, leukemia (CFU-L) are examined as a 
measure of cells capable of continued leukemic growth. 
Approximately 25 microliters of cell suspension are taken 
from each sample and plated in Wells containing culture 
medium consisting of IMDM+10% FBS+(Difco). For 
colony assay, aggregates of at least 40 cells and clusters 
(4—39 cells) are scored after 12—14 days of culture. The 
number of CFU-L are expressed as the number of colonies 
derived from the original suspension culture (S5). 
Finally, the results seen With leukemic cell lines are 
correlated With selected agents and combinations of agents, 
against de novo acute leukemia cells. Therapeutic apheresis 
results in the removal of large quantities of leukemia cells 
from patients presenting With a high degree of leukocytosis 
(generally blast count greater than 100,000/CC3). These 
large numbers of cells are froZen in liquid nitrogen With 
DMSO in the usual fashion in aliquots. This alloWs for 
repeated examinations from the same patient source and 
alloW for some control regarding the reproducibility of 
results. 
The procedures for measurement of inhibition of prolif 
eration or the induction of differentiation, etc., are as 
described above for the leukemic cell lines noted. These 
techniques have been utiliZed in other studies and are Well 
established in the literature (31). 
As noted above, IC50 values for each agent alone are 
established for comparison purposes. The data softWare 
program, Dose effect analysis With microcomputers” 
(BioSoft, Inc.) (51) analyZed a number of experiments to 
date utiliZing combinations of ATRA and suramin. This 
computer analysis program has been utiliZed to assess and 
has been validated by multiple laboratories (50—52). 
Experiment 2: 
Information derived from the prior experiments described 
above leads to examination of retinoids and anti-groWth 
factor (suramin and NF110) agents alone and in combination 
utiliZing a SCID mouse model of human leukemia prolif 
eration. 
Efficacy of therapeutic agents is a predictor of in vivo 
effects. A relevant animal model system exists for in vivo 
testing of agents and combinations of agents. 
Methods 
SCID mice Weighing greater than 25 grams are utiliZed as 
host animals for human acute leukemia cell lines Which have 
been established in in-vitro culture (56). 1x10 cells are 
injected either intravenously or subcutaneously as appropri 
ate to the experiment. As 2 of the cell lines (NB4 and 
NB4.306) must be groWn in SCID mice, the number of cells 
to be injected may vary and a cell dose compatible With 
leukemic cell engraftment are established for those cell lines 
separately. 
Immune de?cient SCID mice are utiliZed. Cells are inocu 
lated into animals With minimal numbers of animals con 
sisting of 5 per control/treatment group. The cell lines are 
inoculated either intravenously (56) or subcutaneously (57) 
at a dose of from 106 to 108 per animal as established for 
engraftment for the individual cell lines being utiliZed. Mice 
receiving intravenous inoculations are pre-treated one to tWo 
days prior to injection With 200 reds of sub-lethal irradiation 
to enhance marroW engraftment of the leukemic cell line as 
per published procedures (56). This sub-lethal dose may 
enhance acceptance of xenografts by diminishing any natu 
ral killer cell activity. 
Subsequent to leukemic cell engraftment, treatment of the 
animals commences 1 Week after leukemia cell injection. 
Treatment is daily for 5 days and dosages conform to ATRA 
Work or derived from in vitro concentrations from the 
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experiments above and pharmacokinetic information on 
suramin (58). ATRA is administered orally through a gavage 
needle. Suramin is administered by intravenous or intrap 
eritoneal injection. 
These mice are examined at least once and usually tWice 
daily and premorbid signs such as hunching, lack of 
mobility, or other clear signs of animal distress result in the 
animal being sacri?ced by cervical dislocation (59). 
Alternatively, the animals injected by the subcutaneous 
route have their tumors measured on a daily basis and When 
such tumors reach 1.5 centimeters in siZe, these animals are 
sacri?ced (57). 
Tissues are obtained at the time of animal sacri?ce from 
representative animals include blood specimen for blood 
smear and assessment of leukemic cell groWth, one femur 
from Which bone marroW smears Will be made and 
examined, and in the case of the subcutaneously injected 
animals, the resulting tumor are surgically excised and touch 
preps made and examined. The histologic examinations 
assure that the animal indeed did have engraftment of the 
human acute leukemia cell line and that it Was responsible 
for the animal’s death. 
Outcomes of groups of animals per control or treatment 
group are used to derive mean+standard error of the mean as 
regards survival. In the case of subcutaneous leukemic cell 
injection, bidimensional tumor measurements (by calibers) 
on a set day post injection (de?ned by hoW Well the 
individual lines engraft and groW) are compared similarly 
betWeen groups. Comparison of treatment groups versus 
control are analyZed. 
Experiment 3: 
Potential mechanisms of AT RA/suramin synergistic activ 
ity are investigated as they relate to cytokine receptor 
density on treated human leukemia cells. 
Data indicates synergism, i.e., supra-additive activity, of 
ATRA plus suramin. Synergism is often obtained When tWo 
agents are interfering With a common metabolic pathWay. In 
this case, it is believe that ATRA may diminish GM-CSF 
receptors on the surface of leukemia cells in a fashion 
analogous to doWn regulation of IL-6 receptors (60) and 
TNF receptors (61) on myeloma and lymphoma cells, 
respectively. This theoretically potentiates the cytokine 
(GM-CSF)—receptor blockade Which is believed to be a 
major mechanism of suramin activity. 
Methods: Human leukemic cell lines (NB4, HL-60) are 
treated With a selected retinoid, suramin, or a combination 
for 8—24 hours. These cells are analyZed by How analysis 
(FACs Scar, Becton Dickenson) for GM-CSF receptors after 
application of monoclonal antibodies directed against either 
GM-CSFRO. or GM-CSFB (Santa CruZ Biotech, Inc.) With 
labeled FITC/anti-mouse second antibody. These analyses 
are conducted by the Cancer Center’s FloW Analysis Core 
Facility and folloW previously published methodology. 
Results of treatment is compared to appropriately matched 
control samples. Testing of selected agents/combinations 
against fresh human leukemia samples to con?rm cell line 
results is anticipated. 
Comparisons of relative receptor density betWeen treated 
and matched control samples are analyZed to ascertain 
statistical differences. 
In conclusion: 
1. Suramin is active against HL60 (as previously reported 
by others also) and is also active against HL-60R and 
NB4. 
2. The combination of ATRA and suramin is synergistic 
against HL-60; this is found in the HL60R cells at higer 
ATRA concentrations tested. 
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3. The combination of suramin and Ara-C is additive 
using this methodology, as Well as y interferon and 
suramin. 
4. Synergism betWeen suramin and ATRA is believed to 
relates to their mode of action. Suramin interacts With 
cytokines and thus may interrupt autocrine groWth 
factor loops Which have been described for acute 
leukemia. ATRA, along With its activity in the nucleus, 
results in the reduction of cytokine receptors. It is 
believed that both of these agents are therefore inter 
acting against autocrine signal transduction pathWays, 
one by interfering With cytokine-receptor interaction 
and the other, by doWn modulating the number of 
receptors available. 
5. The combination of suramin and ot-interferon is syn 
ergistic. 
PHARMACEUTICAL EXAMPLE 
Further, the composition of the present invention is useful 
in pharmaceutical formulation for systemic administration 
to humans and animals in unit dosage forms, such as tablets, 
capsules, pills, poWders, granules, suppositories, sterile 
parenteral solutions or suspensions, sterile non-parenteral 
solutions or suspensions oral solutions or suspensions, oil in 
Water or Water in oil emulsions and the like, containing 
suitable quantities of an active ingredient. Topical applica 
tion can be in the form of ointments, creams, lotions, jellies, 
sprays, douches, and the like. For oral administration either 
solid or ?uid unit dosage forms can be prepared With the 
compositions of the invention. The compositions are useful 
in pharmaceutical compositions (Wt %) of the active ingre 
dient With a carrier or vehicle in the composition in about 1 
to 20% and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For eXample, the compo 
sition of the invention can be miXed With conventional 
ingredients such as dicalciumphosphate, magnesium alumi 
num silicate, magnesium stearate, calcium sulfate, starch, 
talc, lactose, acacia, methyl cellulose and functionally simi 
lar materials as pharmaceutical eXcipients or carriers. A 
sustained release formulation may optionally be used. Cap 
sules may be formulated by miXing the compound With a 
pharmaceutical diluent Which is inert and inserting this 
miXture into a hard gelatin capsule having the appropriate 
siZe. If soft capsules are desired a slurry of the compound 
With an acceptable vegetable, light petroleum, or other inert 
oil can be encapsulated by machine into a gelatin capsule. 
Suspensions, syrups and eliXers may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. Avegetable 
oil such as corn oil, peanut oil or saf?oWer oil, for eXample, 
together With ?avoring agents, sWeeteners and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to Water to form a syrup for ?uid unit 
dosages. Hydro-alcoholic pharmaceutical preparations may 
be used having an acceptable sWeetener such as sugar, 
saccharine or a biological sWeetener and a ?avoring agent in 
the form of an eliXer. 
Pharmaceutical compositions for parenteral and supposi 
tory administration can also be obtained using techniques 
standard in the art. 
The above parenteral solutions or suspensions may be 
administered transdermally and, if desired a more concen 
trated sloW release form may be administered. Accordingly, 
incorporation of the active compounds in a sloW release 
matriX may be implemented for administering transder 
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mally. The compounds may be administered transdermally 
at about 1 to 20% of the composition and preferably about 
5 to 15% Wt % of the active ingredient in the vehicle or 
carr1er. 
Transdermal therapeutic systems are self-contained dos 
age forms that, When applied to intact skin, deliver drug(s) 
at a controlled rate to the systemic circulation. Advantages 
of using the transdermal routing include: enhanced thera 
peutic efficacy, reduction in the frequency of dosing, reduc 
tion of side effects due to optimiZation of the blood 
concentration versus time pro?le, increased patient 
compliance due to elimination of multiple dosing schedules, 
bypassing the hepatic “?rst-pass” metabolism, avoiding 
gastrointestinal incompatibilities and providing a predict 
able and extended duration of activity. HoWever, the main 
function of the skin is to act as a barrier to entering 
compounds. As a consequence, transdermal therapy has so 
far been restricted to a limited number of drugs that possess 
the desirable physicochemical properties for diffusion across 
the skin barrier. One effective method of overcoming the 
barrier function of the skin is to include a penetration 
enhancer in the formulation of a transdermal therapeutic 
system. See Barry, Brian W.: Dermatological Formulations: 
Percutaneous Absorption (Dekker, NeW York, 1983); 
Bronough et al, Percutaneous Absorption, Mechanisms 
Methodology-Drug Delivery, (Marcel Dekker, NeW York, 
NY 1985); and Monkhouse et al, Transdermal drug deliver 
problems and promises. Drug Dev. Ind. Pharm., 14, 
183—209 (1988). 
A penetration enhancer is a chemical compound that, 
When included in a formulation, temporarily increases the 
permeability of the skin to a drug alloWing more of the drug 
to be absorbed in a shorter period of time. Several different 
types of penetration enhancers have been reported such as 
dimethylsulfoXide, n-decyl methyl sulfoXide, N,N 
dimethylacetamide, N<Ni-dimethylformamide, 
1-dodecylaZacycloheptan-2-one (AZone), propylene glycol, 
ethanol, pyrrolidones such as N-methyl-2-pyrrrolidone 
(NMP) and surfactants. See Bronough et al, supra, and 
Stoughton et al, AZone: a NeW Non-toxic enhancer of 
percutaneous penetration. Drug Dev. Inc. Pharm., 9, 
725—744 (1983). 
N-methyl-2-pyrrolidone is a versatile solvent Which is 
miscible With Water, ethyl alcohol, ether, chloroform, 
benZene, ethyl acetate and carbon disul?de. 
N-methylpyrrolidone has been Widely used as a solvent in 
industrial processes such as petroleum re?ning, GAF Corp.: 
“M-Pyrol (N-methyl-2-pyrrolidone) Handbook”, GAF 
Corp., NeW York, 1972. It is currently used as a solubiliZing 
agent in topical and parenteral veterinary pharmaceuticals 
and is noW under consideration for use in products intended 
for humans, Wells, D. A. et al: Disposition and Metabolism 
of Double-Labeled [3H and 14C] N-methyl-2-pyrrolidone in 
the Rat. Drug Met. Disps., 16, 243—249 (1988). Animal and 
human experiments have shoWn very little irritation or 
sensitiZation potential. Ames type assays and chronic eXpo 
sure studies have not revealed any signi?cant toXicity, Wells 
et al, Mutagenicity and CytotoXicity of N-methyl-2-p 
[yrrolidone and 4-(methyl amino) Butanoic Acid in the 
Salmonella/microsome Assay. J. Appl. Tox., 8, 135—139 
(1988). N-methylpyrrolidone has also been shoWn to be an 
effective penetration enhancer. Barry et al, OptimiZation and 
Bioavailability of Topical Steroids: Penetration Enhancers 
Under Occlusion. J. Inv. Derm., 82, 49—52 (1984); Effect of 
Dose Variation, Deposited Drug Films, Occlusion and the 
Penetration Enhancer N-methyl-2-pyrrolidone. J. Pharm. 
Pharmacol, 37, 27—37 (1984); Holegaard et al, Vesical 
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Effect on Topical Drug Delivery IV. Effect of 
N-methylpyrrolidone and Polar Lipids on Percutaneous 
Transport. Int. J. Pharm, 43, 233—240 (1988); Sugibayashi 
et al, Effect of Several Penetration Enhancers on the Percu 
taneous Absorption of Indomethacin in Hairless Rat. Chem. 
Pharm. BulL, 36, 1519—1529 (1988); Bennett et al, Optimi 
Zation of Bioavailability of Topical Steroids: Non-occluded 
penetration Enhancers Under Thermodynamic Control. J. 
Pharm. PharmacoL, 37, 298—304 (1985); Sasaki et al, 
Enhancing Effect of Pyrrolidone Derivatives on Transder 
man Drug Delivery. 1. Ing. J. Pharm, 44, 14—24 (1988); lee 
et al, Toxicity of N-methyl-2-pyrrolidone (NMP): 
Tetratogenic, Subchronic and TWo-year Inhalation Studies, 
Fund. AppL, T0x., 9, 222—235 (1987). 
The above and other drugs can be present in the reservoir 
alone or in combination form With pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art knoWn carriers that do not 
adversely affect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile Water; saline, dextrose; dextrose in Water 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; loWer alkanols; oils 
such as corn oil; peanut oil, sesame oil and the like, With 
emulsi?ers such as mono- or di-glyceride of a fatty acid, or 
a phosphatide, e.g., lecithin, and the like; glycols; polyalky 
lene glycols; aqueous media in the presence of a suspending 
agent, for example, sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrolidone); and the like, alone, or With 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving stabilizing, Wetting, emulsifying agents 
and the like together With the penetration enhancer of this 
invention. 
The effective dosage for mammals may vary due to such 
factors as age, Weight activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
compound according to the present invention is about 45mg/ 
M2/d/po for AT RA, 200—1100 mg M2/d/iv; and 3—10 million 
units/d subcutaneous for ot-interferon daily, or preferably 
about three times per Week. 
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The purpose of the above description and eXamples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention Without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
What is claimed is: 
1. A method of treating leukemia comprising administer 
ing a synergistic composition comprising suramin and all 
trans retinoic acid (ATRA) at a ratio of about 14:1 to about 
3500:1. 
2. The method according to claim 1, Wherein the amount 
of suramin is at least about 3.5 pM, and all-trans retinoic 
acid (ATRA) is at least about 0.002 pM. 
3. The method according to claim 2, Wherein the amount 
of suramin is at least about 7 pM, and all-trans retinoic acid 
(AT RA) is at least about 0.002 pM. 
4. The method according to claim 3, Wherein the amount 
of suramin is at least about 14 pM, and all-trans retinoic acid 
(AT RA) is at least about 0.004 pM. 
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5. The method according to claim 2, Wherein the amount 
of suramin is in a range of about 3.5 to about 56 pM, and the 
amount of all-trans retinoic acid (ATRA) is in a range of 
about 0.001 to 4 pM. 
6. The method according to claim 5, Wherein the amount 
of suramin is in a range of about 7 to about 56 pM, and the 
amount of all-trans retinoic acid (ATRA) is in a range of 
about 0.002 to about 4 pM. 
7. The method according to claim 1, Wherein the ratio is 
about 350:1. 
8. A synergistic pharmaceutical composition for treating 
leukemia comprising suramin and all-trans retinoic acid 
(ATRA) at a ratio of about 14:1 to about 3500:1. 
9. The pharmaceutical composition according to claim 8, 
Wherein the amount of suramin is at least about 3.5 pM, and 
all-trans retinoic acid (ATRA) is at least about 0.002 pM. 
10. The pharmaceutical composition according to claim 9, 
Wherein the amount of suramin is at least about 7 pM, and 
all-trans retinoic acid (ATRA) is at least about 0.002 pM. 
11. The pharmaceutical composition according to claim 
10, Wherein the amount of suramin is at least about 14 pM 
and all-trans retinoic acid (ATRA) is at least about 0.004 
pM. 
12. The pharmaceutical composition according to claim 9, 
Wherein the amount of suramin is in a range of about 3.5 to 
about 56 pM, and the amount of all-trans retinoic acid 
(ATRA) is in a range of about 0.001 to 4 pM. 
13. The pharmaceutical composition according to claim 
12, Wherein the amount of suramin is in a range of about 7 
to about 56 pM, and the amount of all-trans retinoic acid 
(ATRA) is in a range of about 0.002 to about 4 pM. 
14. The pharmaceutical composition according to claim 8, 
Wherein the ratio is about 350:1. 
